Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 268
Filtrer
1.
Free Radic Biol Med ; 194: 245-254, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36509314

RÉSUMÉ

The accumulation of all-trans-retinal (atRAL) in photoreceptors and the retinal pigment epithelium (RPE), which is induced by chaos in visual (retinoid) cycle, is closely associated with the pathogenesis of dry age-related macular degeneration (AMD) and autosomal recessive Stargardt's disease (STGD1). Although we have reported that the induction of ferroptosis by atRAL is an important cause of photoreceptor loss, but its mechanisms still remain unclear. In this study, we identified heme oxygenase-1 (HO-1) as an inducer of photoreceptor ferroptosis elicited by atRAL. In atRAL-loaded photoreceptor cells, inhibition of Kelch-like ECH-associated protein 1 (KEAP1) at least in part by reactive oxygen species (ROS) production evoked the release of nuclear factor-erythroid 2-related factor-2 (NRF2) from KEAP1, followed by the translocation of active NRF2 into the nucleus where it promoted the transcription of the Ho-1 gene, thereby leading to HO-1 overexpression in the cytosol. A significant elevation of Fe2+ levels in photoreceptor cells resulted from activation of HO-1 by atRAL, and it facilitated ROS overproduction and then triggered ferroptotic cell death through ROS-mediated lipid peroxidation. Both treatment with HO-1 repressor Zinc protoporphyrin IX (ZnPP) and knockout of Ho-1 gene clearly rescued photoreceptor cells against ferroptosis arising from atRAL overload. Light-exposed Abca4-/-Rdh8-/- mice rapidly display severe defects in atRAL clearance, and serve as an acute model of dry AMD and STGD1. HO-1 activation was distinctly observed in neural retina of Abca4-/-Rdh8-/- mice after exposure to light, and it was visibly relieved by intraperitoneally injected ferroptosis inhibitor ferrostatin-1. More notably, intraperitoneal administration of ZnPP effectively alleviated both photoreceptor degeneration and RPE atrophy in Abca4-/-Rdh8-/- mice in response to light exposure by repressing HO-1-mediated ferroptosis. Our study suggests that HO-1 is a key factor that regulates atRAL-induced ferroptosis in photoreceptors and the RPE, and its inhibition may hold promises for the therapy of dry AMD and STGD1.


Sujet(s)
Ferroptose , Dégénérescence de la rétine , Animaux , Souris , Dégénérescence de la rétine/anatomopathologie , Rétinal/métabolisme , Rétinal/pharmacologie , Protéine-1 de type kelch associée à ECH/génétique , Protéine-1 de type kelch associée à ECH/métabolisme , Espèces réactives de l'oxygène/métabolisme , Ferroptose/génétique , Heme oxygenase-1/génétique , Heme oxygenase-1/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Facteur-2 apparenté à NF-E2/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Transporteurs ABC/génétique
2.
Mol Med ; 28(1): 125, 2022 10 22.
Article de Anglais | MEDLINE | ID: mdl-36273174

RÉSUMÉ

BACKGROUND: Oxidative stress-caused damage to the retinal pigment epithelium (RPE) underlies the onset and progression of age-related macular degeneration (AMD). Impaired mitochondrial biogenesis sensitizes RPE cells to mitochondrial dysfunction, energy insufficiency and death. Src-homology 2 domain-containing phosphatase (SHP)-1 is important in regulating immune responses and cell survival. However, its roles in cell survival are not always consistent. Until now, the effects of SHP-1 on RPE dysfunction, especially mitochondrial homeostasis, remain to be elucidated. We sought to clarify the effects of SHP-1 in RPE cells in response to atRAL-induced oxidative stress and determine the regulatory mechanisms involved. METHODS: In the all trans retinal (atRAL)-induced oxidative stress model, we used the vector of lentivirus to knockdown the expression of SHP-1 in ARPE-19 cells. CCK-8 assay, Annexin V/PI staining and JC-1 staining were utilized to determine the cell viability, cell apoptosis and mitochondrial membrane potential. We also used immunoprecipitation to examine the ubiquitination modification of stimulator of interferon genes (STING) and its interaction with SHP-1. The expression levels of mitochondrial marker, proteins related to mitochondrial biogenesis, and signaling molecules involved were examined by western blotting analysis. RESULTS: We found that SHP-1 knockdown predisposed RPE cells to apoptosis, aggravated mitochondrial damage, and repressed mitochondrial biogenesis after treatment with atRAL. Immunofluoresent staining and immunoprecipitation analysis confirmed that SHP-1 interacted with the endoplasmic reticulum-resident STING and suppressed K63-linked ubiquitination and activation of STING. Inhibition of STING with the specific antagonist H151 attenuated the effects of SHP-1 knockdown on mitochondrial biogenesis and oxidative damage. The adenosine monophosphate-activated protein kinase (AMPK) pathway acted as the crucial downstream target of STING and was involved in the regulatory processes. CONCLUSIONS: These findings suggest that SHP-1 knockdown potentiates STING overactivation and represses mitochondrial biogenesis and cell survival, at least in part by blocking the AMPK pathway in RPE cells. Therefore, restoring mitochondrial health by regulating SHP-1 in RPE cells may be a potential therapeutic strategy for degenerative retinal diseases including AMD.


Sujet(s)
Dégénérescence maculaire , Mitochondries , Épithélium pigmentaire de la rétine , Rétinal , Humains , AMP/métabolisme , AMP/pharmacologie , AMP-Activated Protein Kinases/métabolisme , Annexine A5/métabolisme , Annexine A5/pharmacologie , Apoptose/génétique , Interférons/génétique , Interférons/métabolisme , Interférons/pharmacologie , Dégénérescence maculaire/génétique , Dégénérescence maculaire/métabolisme , Mitochondries/métabolisme , Biogenèse des organelles , Stress oxydatif , Phosphoric monoester hydrolases/métabolisme , Phosphoric monoester hydrolases/pharmacologie , Espèces réactives de l'oxygène/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Épithélium pigmentaire de la rétine/anatomopathologie , Rétinal/métabolisme , Rétinal/pharmacologie
3.
PLoS One ; 17(10): e0269437, 2022.
Article de Anglais | MEDLINE | ID: mdl-36227868

RÉSUMÉ

The visual cycle refers to a series of biochemical reactions of retinoids in ocular tissues and supports the vision in vertebrates. The visual cycle regenerates visual pigments chromophore, 11-cis-retinal, and eliminates its toxic byproducts from the retina, supporting visual function and retinal neuron survival. Unfortunately, during the visual cycle, when 11-cis-retinal is being regenerated in the retina, toxic byproducts, such as all-trans-retinal and bis-retinoid is N-retinylidene-N-retinylethanolamine (A2E), are produced, which are proposed to contribute to the pathogenesis of the dry form of age-related macular degeneration (AMD). The primary biochemical defect in Stargardt disease (STGD1) is the accelerated synthesis of cytotoxic lipofuscin bisretinoids, such as A2E, in the retinal pigment epithelium (RPE) due to mutations in the ABCA4 gene. To prevent all-trans-retinal-and bisretinoid-mediated retinal degeneration, slowing down the retinoid flow by modulating the visual cycle with a small molecule has been proposed as a therapeutic strategy. The present study describes RPE65-61, a novel, non-retinoid compound, as an inhibitor of RPE65 (a key enzyme in the visual cycle), intended to modulate the excessive activity of the visual cycle to protect the retina from harm degenerative diseases. Our data demonstrated that (±)-RPE65-61 selectively inhibited retinoid isomerase activity of RPE65, with an IC50 of 80 nM. Furthermore, (±)-RPE65-61 inhibited RPE65 via an uncompetitive mechanism. Systemic administration of (±)-RPE65-61 in mice resulted in slower chromophore regeneration after light bleach, confirming in vivo target engagement and visual cycle modulation. Concomitant protection of the mouse retina from high-intensity light damage was also observed. Furthermore, RPE65-61 down-regulated the cyclic GMP-AMP synthase stimulator of interferon genes (cGAS-STING) pathway, decreased the inflammatory factor, and attenuated retinal apoptosis caused by light-induced retinal damage (LIRD), which led to the preservation of the retinal function. Taken together, (±)-RPE65-61 is a potent visual cycle modulator that may provide a neuroprotective therapeutic benefit for patients with STGD and AMD.


Sujet(s)
Dégénérescence maculaire , Dégénérescence de la rétine , Transporteurs ABC/génétique , Transporteurs ABC/métabolisme , Animaux , Interférons/métabolisme , Lipofuscine/métabolisme , Dégénérescence maculaire/traitement médicamenteux , Dégénérescence maculaire/métabolisme , Souris , Nucleotidyltransferases/métabolisme , Cellules photoréceptrices de vertébré/métabolisme , Dégénérescence de la rétine/traitement médicamenteux , Dégénérescence de la rétine/étiologie , Dégénérescence de la rétine/prévention et contrôle , Pigments rétiniens/métabolisme , Rétinal/métabolisme , Rétinal/pharmacologie , Rétinoïdes/métabolisme , Rétinoïdes/pharmacologie , Cis-trans-isomerases/génétique , Cis-trans-isomerases/métabolisme
4.
J Biol Chem ; 298(8): 102266, 2022 08.
Article de Anglais | MEDLINE | ID: mdl-35850308

RÉSUMÉ

Over 100 mutations in the rhodopsin gene have been linked to a spectrum of retinopathies that include retinitis pigmentosa and congenital stationary night blindness. Though most of these variants exhibit a loss of function, the molecular defects caused by these underlying mutations vary considerably. In this work, we utilize deep mutational scanning to quantitatively compare the plasma membrane expression of 123 known pathogenic rhodopsin variants in the presence and absence of the stabilizing cofactor 9-cis-retinal. We identify 69 retinopathy variants, including 20 previously uncharacterized variants, that exhibit diminished plasma membrane expression in HEK293T cells. Of these apparent class II variants, 67 exhibit a measurable increase in expression in the presence of 9-cis-retinal. However, the magnitude of the response to this molecule varies considerably across this spectrum of mutations. Evaluation of the observed shifts relative to thermodynamic estimates for the coupling between binding and folding suggests underlying differences in stability constrains the magnitude of their response to retinal. Nevertheless, estimates from computational modeling suggest that many of the least sensitive variants also directly compromise binding. Finally, we evaluate the functional properties of three previous uncharacterized, retinal-sensitive variants (ΔN73, S131P, and R135G) and show that two of these retain residual function in vitro. Together, our results provide a comprehensive experimental characterization of the proteostatic properties of retinopathy variants and their response to retinal.


Sujet(s)
Maladies héréditaires de l'oeil , Rhodopsine , Diterpènes/pharmacologie , Résistance aux substances/génétique , Maladies héréditaires de l'oeil/génétique , Cellules HEK293 , Humains , Mutation , Rétinal/pharmacologie , Rhodopsine/effets des médicaments et des substances chimiques , Rhodopsine/génétique , Rhodopsine/métabolisme
5.
Int J Cosmet Sci ; 44(2): 201-215, 2022 Apr.
Article de Anglais | MEDLINE | ID: mdl-35238059

RÉSUMÉ

OBJECTIVE: Because they limit, even reverse, age-induced skin alterations, retinoids became a staple in cosmetology. However, their use can result in undesired secondary effects and there is a demand for natural sources of compounds with retinoid-like effects. A preliminary screening identified a Harungana madagascariensis plant extract (HME) as possibly inducing genes stimulated by retinol. We analysed its effect on gene and protein expression, comparing it to retinoids. METHODS: Gene expression was analysed by real-time qPCR on RNA from isolated fibroblasts subjected to retinol or the plant extract for 6, 48 or 96 h. Skin markers were quantified in fibroblasts cultured with retinol or extract containing medium, and UV-aged skin explants subjected to topical applications of creams containing retinol, retinaldehyde or HME. RESULTS: Real-time qPCR shows that the extract induced all RARs and RXRs, even RXRγ that was not induced by retinol. Eighty-eight per cent of the 25 early retinoid reaction genes induced by a concentration of retinol are induced by the extract. In fibroblasts, only the extract increased collagen III labelling, while collagen I and fibronectin labelling are increased by retinol and the extract, with higher levels for the extract. When topically applied to UV-aged skin explants, only the cream containing the HME led to increased labelling of CRABP1 in the epidermis. CRABP2 and Ki67 are induced by all three creams and no effect was detected on RXRs. In the dermisthe extract containing cream increased CRABP2, total collagen, procollagen I and collagen I while creams with retinol or retinaldehyde only affected some of these proteins. CONCLUSIONS: The HME induces an overall retinol-like gene induction profile in isolated fibroblasts and retinoid-like stimulation of protein synthesis in both isolated fibroblasts and photoaged skin explants.


OBJECTIFS: Limitant, voire inversant les altérations cutanées induites par l'âge, les rétinoïdes sont devenus incontournables en cosmétologie. Cependant, leur application topique peut entraîner des effets secondaires indésirables et il existe une demande pour des composés naturels ayant des effets similaires à ceux des rétinoïdes. Un screening préliminaire nous avait permis d'identifier un extrait de la plante Harungana madagascariensis (HME) comme pouvant induire des gènes stimulés par le rétinol. Nous avons donc analysé son effet sur l'expression de gènes et de protéines induits par les rétinoïdes et comparé les résultats à ceux obtenus en présence de rétinoïdes. MÉTHODES: L'expression de gènes a été analysée par qPCR en temps réel réalisée sur l'ARN de fibroblastes isolés soumis au rétinol ou à l'extrait végétal pendant 6, 48 ou 96 heures. Différentes protéines cutanées ont été quantifiés dans des fibroblastes cultivés en présence de rétinol ou d'un milieu contenant l'extrait. Des quantifications ont également été faites sur des explants de peau vieillie par les UV et soumis à des applications topiques de crèmes contenant du rétinol, du rétinaldéhyde ou le HME. RESULTATS: La qPCR en temps réel montre que l'extrait induit tous les gènes RARs et RXRs, même RXRγ qui n'était pas induit par le rétinol. Quatre-vingt-huit pour cent des 25 gènes impliqués dans la réaction précoce aux rétinoïdes induits par une concentration de rétinol ont été induits par l'extrait. Dans les fibroblastes, seul l'extrait a augmenté le marquage du collagène III, tandis que le marquage du collagène I et de la fibronectine a été augmenté par le rétinol et l'extrait, avec des niveaux plus élevés pour l'extrait. En application topique sur des explants de peau vieillie par les UV, seule la crème contenant le HME a entraîné une augmentation du marquage de CRABP1 dans l'épiderme. CRABP2 et Ki67 ont été induits par les trois crèmes et aucun effet n'a été détecté sur les RXRs. Dans le derme, la crème contenant l'extrait a augmenté CRABP2, le collagène total, le procollagène I et le collagène I, tandis que les crèmes contenant du rétinol ou du rétinaldéhyde n'ont affecté que certaines de ces protéines. CONCLUSIONS: Chez les fibroblastes isolés, le HME induit un profil d'induction génique globalement similaire à celui du rétinol. Chez les fibroblastes isolés et des explants de peau photo-vieillie, il entraine une stimulation de la synthèse protéique similaire à celle des rétinoïdes.


Sujet(s)
Rétinal , Rétinol , Sujet âgé , Collagène/métabolisme , Collagène de type I/génétique , Collagène de type I/métabolisme , Fibroblastes , Humains , Extraits de plantes/pharmacologie , Rétinal/métabolisme , Rétinal/pharmacologie , Rétinoïdes/pharmacologie , Peau , Régulation positive , Rétinol/pharmacologie
6.
Science ; 373(6562): 1532-1536, 2021 Sep 24.
Article de Anglais | MEDLINE | ID: mdl-34446443

RÉSUMÉ

In Arabidopsis, de novo organogenesis of lateral roots is patterned by an oscillatory mechanism called the root clock, which is dependent on unidentified metabolites. To determine whether retinoids regulate the root clock, we used a chemical reporter for retinaldehyde (retinal)­binding proteins. We found that retinal binding precedes the root clock and predicts sites of lateral root organogenesis. Application of retinal increased root clock oscillations and promoted lateral root formation. Expression of an Arabidopsis protein with homology to vertebrate retinoid-binding proteins, TEMPERATURE INDUCED LIPOCALIN (TIL), oscillates in the region of retinal binding to the reporter, confers retinal-binding activity in a heterologous system, and, when mutated, decreases retinal sensitivity. These results demonstrate a role for retinal and its binding partner in lateral root organogenesis.


Sujet(s)
Protéines d'Arabidopsis/métabolisme , Arabidopsis/croissance et développement , Arabidopsis/métabolisme , Lipocalines/métabolisme , Racines de plante/croissance et développement , Rétinal/métabolisme , Arabidopsis/génétique , Protéines d'Arabidopsis/composition chimique , Protéines d'Arabidopsis/génétique , Fluorescence , Lipocalines/composition chimique , Lipocalines/génétique , Méristème/métabolisme , Mutation , Organogenèse des plantes , Racines de plante/métabolisme , Liaison aux protéines , Pyrimidinones/métabolisme , Rétinal/pharmacologie , Transduction du signal
7.
J Cell Physiol ; 236(5): 3660-3674, 2021 05.
Article de Anglais | MEDLINE | ID: mdl-33034385

RÉSUMÉ

The underlying mechanisms of complement activation in Stargardt disease type 1 (STGD1) and age-related macular degeneration (AMD) are not fully understood. Overaccumulation of all-trans-retinal (atRAL) has been proposed as the pathogenic factor in both diseases. By incubating retinal pigment epithelium (RPE) cells with atRAL, we showed that C5b-9 membrane attack complexes (MACs) were generated mainly through complement alternative pathway. An increase in complement factor B (CFB) expression as well as downregulation of complement regulatory proteins CD46, CD55, CD59, and CFH were observed in RPE cells after atRAL treatment. Furthermore, interleukin-1ß production was provoked in both atRAL-treated RPE cells and microglia/macrophages. Coincubation of RPE cells with interleukin-1 receptor antagonist (IL1Ra) and atRAL ameliorated complement activation and downregulated CFB expression by attenuating both p38 and c-Jun N-terminal kinase (JNK) signaling pathways. Our findings demonstrate that atRAL induces an autocrine/paracrine IL-1/IL-1R signaling to promote complement alternative pathway activation in RPE cells and provide a novel perspective on the pathomechanism of macular degeneration.


Sujet(s)
Activation du complément/effets des médicaments et des substances chimiques , Voie alterne d'activation du complément/effets des médicaments et des substances chimiques , Interleukine-1/métabolisme , Récepteurs à l'interleukine-1/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Rétinal/pharmacologie , Transduction du signal , Acétylcystéine/pharmacologie , Animaux , Cellules cultivées , Facteur B du complément/métabolisme , Régulation négative , Humains , Interleukine-1/génétique , Macrophages/effets des médicaments et des substances chimiques , Macrophages/métabolisme , Souris , Microglie/effets des médicaments et des substances chimiques , Microglie/métabolisme , Mitogen-Activated Protein Kinase 8/métabolisme , Modèles biologiques , Épithélium pigmentaire de la rétine/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiques , Suidae , Transcription génétique/effets des médicaments et des substances chimiques , Régulation positive/effets des médicaments et des substances chimiques , p38 Mitogen-Activated Protein Kinases/métabolisme
8.
J Neurogenet ; 34(3-4): 466-474, 2020.
Article de Anglais | MEDLINE | ID: mdl-32543249

RÉSUMÉ

Optogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light. This method has revolutionized biology and medicine as it allows controlling cells with high temporal and spatial precision. Optogenetics is typically applied only at short time scales, for instance to study specific behaviors. Optogenetically manipulating behavior also gives insights into physiology, as behavior controls systemic physiological processes. For example, arousal and sleep affect aging and health span. To study how behavior controls key physiological processes, behavioral manipulations need to occur at extended time scales. However, methods for long-term optogenetics are scarce and typically require expensive compound microscope setups. Optogenetic experiments can be conducted in many species. Small model animals such as the nematode C. elegans have been instrumental in solving the mechanistic basis of medically important biological processes. We developed the OptoGenBox, an affordable stand-alone and simple-to-use device for long-term optogenetic manipulation of C. elegans. The OptoGenBox provides a controlled environment and is programmable to allow the execution of complex optogenetic manipulations over long experimental times of many days to weeks. To test our device, we investigated how optogenetically increased arousal and optogenetic sleep deprivation affect survival of arrested first larval stage C. elegans. We optogenetically activated the nociceptive ASH sensory neurons using ReaChR, thus triggering an escape response and increase in arousal. In addition, we optogenetically inhibited the sleep neuron RIS using ArchT, a condition known to impair sleep. Both optogenetic manipulations reduced survival. Thus, the OptoGenBox presents an affordable system to study the long-term consequences of optogenetic manipulations of key biological processes in C. elegans and perhaps other small animals.


Sujet(s)
Caenorhabditis elegans/physiologie , Optogénétique/instrumentation , Animaux , Éveil/physiologie , Caenorhabditis elegans/croissance et développement , Protéines de Caenorhabditis elegans/génétique , Protéines de Caenorhabditis elegans/physiologie , Conception d'appareillage , Réaction de fuite/physiologie , Larve , Longévité , Neurones/physiologie , Nocicepteurs/physiologie , Optogénétique/méthodes , Plan de recherche , Rétinal/pharmacologie , Sommeil/physiologie , Privation de sommeil/physiopathologie
9.
Am J Pathol ; 190(7): 1505-1512, 2020 07.
Article de Anglais | MEDLINE | ID: mdl-32275905

RÉSUMÉ

Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness among the working-age population. Diabetic patients often experience functional deficits in dark adaptation, contrast sensitivity, and color perception before any microvascular pathologies on the fundus become detectable. Previous studies showed that the regeneration of 11-cis-retinal and visual pigment is impaired in a type 1 diabetes animal model, which negatively affects visual function at the early stage of DR. Here, Akita mice, type 1 diabetic model, were treated with the visual pigment chromophore, 9-cis-retinal. This treatment rescued a- and b-wave amplitudes of scotopic electroretinography responses, compared with vehicle-treated Akita mice. In addition, the administration of 9-cis-retinal alleviated oxidative stress significantly as shown by reduced 3-nitrotyrosine levels in the retina of Akita mice. Furthermore, the 9-cis-retinal treatment decreased retinal apoptosis as shown by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and DNA fragment enzyme-linked immunosorbent assay. Overall, these findings showed that 9-cis-retinal administration restored visual pigment formation and decreased oxidative stress and retinal degeneration, which resulted in improved visual function in diabetic mice, suggesting that chromophore deficiency plays a causative role in visual defects in early DR.


Sujet(s)
Rétinopathie diabétique/physiopathologie , Diterpènes/pharmacologie , Rétine/effets des médicaments et des substances chimiques , Rétinal/pharmacologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Diabète expérimental/complications , Diabète de type 1/complications , Mâle , Souris , Souris de lignée C57BL , Souches mutantes de souris , Stress oxydatif/effets des médicaments et des substances chimiques , Rétine/physiopathologie
10.
J Biol Chem ; 295(20): 6958-6971, 2020 05 15.
Article de Anglais | MEDLINE | ID: mdl-32265302

RÉSUMÉ

Disrupted clearance of all-trans-retinal (atRAL), a component of the visual (retinoid) cycle in the retina, may cause photoreceptor atrophy in autosomal recessive Stargardt disease (STGD1) and dry age-related macular degeneration (AMD). However, the mechanisms underlying atRAL-induced photoreceptor loss remain elusive. Here, we report that atRAL activates c-Jun N-terminal kinase (JNK) signaling at least partially through reactive oxygen species production, which promoted mitochondria-mediated caspase- and DNA damage-dependent apoptosis in photoreceptor cells. Damage to mitochondria in atRAL-exposed photoreceptor cells resulted from JNK activation, leading to decreased expression of Bcl2 apoptosis regulator (Bcl2), increased Bcl2 antagonist/killer (Bak) levels, and cytochrome c (Cyt c) release into the cytosol. Cytosolic Cyt c specifically provoked caspase-9 and caspase-3 activation and thereby initiated apoptosis. Phosphorylation of JNK in atRAL-loaded photoreceptor cells induced the appearance of γH2AX, a sensitive marker for DNA damage, and was also associated with apoptosis onset. Suppression of JNK signaling protected photoreceptor cells against atRAL-induced apoptosis. Moreover, photoreceptor cells lacking Jnk1 and Jnk2 genes were more resistant to atRAL-associated cytotoxicity. The Abca4-/-Rdh8-/- mouse model displays defects in atRAL clearance that are characteristic of STGD1 and dry AMD. We found that JNK signaling was activated in the neural retina of light-exposed Abca4-/-Rdh8-/- mice. Of note, intraperitoneal administration of JNK-IN-8, which inhibits JNK signaling, effectively ameliorated photoreceptor degeneration and apoptosis in light-exposed Abca4-/-Rdh8-/- mice. We propose that pharmacological inhibition of JNK signaling may represent a therapeutic strategy for preventing photoreceptor loss in retinopathies arising from atRAL overload.


Sujet(s)
Apoptose/effets des médicaments et des substances chimiques , Mitogen-Activated Protein Kinase 8/métabolisme , Mitogen-Activated Protein Kinase 9/métabolisme , Cellules photoréceptrices de vertébré/métabolisme , Rétinal/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Maladie de Stargardt/métabolisme , Transporteurs ABC/génétique , Transporteurs ABC/métabolisme , Alcohol oxidoreductases/génétique , Alcohol oxidoreductases/métabolisme , Animaux , Apoptose/génétique , Souris , Souris knockout , Mitogen-Activated Protein Kinase 8/génétique , Mitogen-Activated Protein Kinase 9/génétique , Cellules photoréceptrices de vertébré/anatomopathologie , Transduction du signal/génétique , Maladie de Stargardt/génétique , Maladie de Stargardt/anatomopathologie
11.
Mol Vis ; 25: 663-678, 2019.
Article de Anglais | MEDLINE | ID: mdl-31814692

RÉSUMÉ

PURPOSE: Retinal organoids generated from human pluripotent stem cells exhibit considerable variability during differentiation. Our goals are to assess developmental maturity of the neural retina in vitro and design improved protocols based on objective criteria. METHODS: We performed transcriptome analyses of developing retinal organoids from human embryonic and induced pluripotent stem cell lines and utilized multiple bioinformatic tools for comparative analysis. Immunohistochemistry, immunoblotting and electron microscopy were employed for validation. RESULTS: We show that the developmental variability in organoids was reflected in gene expression profiles and could be evaluated by molecular staging with the human fetal and adult retinal transcriptome data. We also demonstrate that the addition of 9-cis retinal, instead of the widely used all-trans retinoic acid, accelerated rod photoreceptor differentiation in organoid cultures, with higher rhodopsin expression and more mature mitochondrial morphology evident by day 120. CONCLUSION: Our studies provide an objective transcriptome-based modality for determining the differentiation state of retinal organoids and for comparisons across different stem cell lines and platforms, which should facilitate disease modeling and evaluation of therapies in vitro.


Sujet(s)
Différenciation cellulaire , Diterpènes/pharmacologie , Cellules souches embryonnaires humaines/cytologie , Organoïdes/cytologie , Rétine/cytologie , Cellules photoréceptrices en bâtonnet de la rétine/cytologie , Rétinal/pharmacologie , Transcriptome/génétique , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaire , Forme de la cellule/effets des médicaments et des substances chimiques , Analyse de profil d'expression de gènes , Cellules souches embryonnaires humaines/effets des médicaments et des substances chimiques , Humains , Cellules souches pluripotentes induites/cytologie , Cellules souches pluripotentes induites/effets des médicaments et des substances chimiques , Organoïdes/effets des médicaments et des substances chimiques , Organoïdes/ultrastructure , Cellules photoréceptrices en bâtonnet de la rétine/effets des médicaments et des substances chimiques , Transcriptome/effets des médicaments et des substances chimiques
12.
Exp Dermatol ; 28(11): 1219-1226, 2019 11.
Article de Anglais | MEDLINE | ID: mdl-31309627

RÉSUMÉ

Ultraviolet light enhances the generation of reactive oxygen species that are responsible for skin photoageing. The aim of this randomized, vehicle- and active-controlled double-blind, intra-individual monocentric study was to evaluate in situ the antioxidant activity of a dermo-cosmetic product in photoaged skin. Twenty healthy volunteers had defined skin areas randomized to receive a topical product containing 3 antioxidants (pre-tocopheryl® , retinaldehyde and glycylglycine ole-amide), its vehicle and a positive antioxidant control cream. The products were applied daily for 30-day period. The skin areas were exposed to a controlled dose of UVA rays, and the skin oxidative status was evaluated 4 and 24 hours post-UVA exposure at D0 (basal value) and after 15 and 30 days of product application. Skin layers were collected by stripping, and antioxidant capacity was measured using the ferric reducing ability of a plasma assay. Lipid peroxidation (LPO) was assessed using the malonyldialdehyde test. The tested product significantly improved the skin antioxidant capacity after 15 and 30 days and significantly decreased the basal level of the skin LPO. The skin LPO level significantly decreased 4 and 24 hours after UVA exposure at 15 and 30 days. These findings were comparable to positive control treated sites and were significantly different from the vehicle and untreated sites. This minimally invasive methodology enabled a quantitative evaluation of potent antioxidant activity in situ in the stratum corneum reflecting real-life skin conditions and confirming the benefits of the topical application of a product containing 3 antioxidants in the prevention of UVA-induced oxidative damage.


Sujet(s)
Antioxydants/pharmacologie , Vieillissement de la peau/effets des médicaments et des substances chimiques , Crème pour la peau/pharmacologie , Adulte , Femelle , Volontaires sains , Humains , Peroxydation lipidique/effets des médicaments et des substances chimiques , Mâle , Adulte d'âge moyen , Rétinal/pharmacologie , Vitamine E/analogues et dérivés , Vitamine E/pharmacologie
13.
Arch Pharm Res ; 41(10): 1009-1018, 2018 Oct.
Article de Anglais | MEDLINE | ID: mdl-30117083

RÉSUMÉ

Abnormal accumulation of the free-form all-trans-retinal (atRAL), a major intermediate of human visual cycle, is considered to be a key cause of retinal pigment epithelial (RPE) dysfunction in the pathogenesis of retinal degenerative diseases such as age-related macular degeneration (AMD). Paeoniflorin (PF), a monoterpene glucoside isolated from Paeonia lactiflora Pall., has been used in clinical treatment of retinal degenerative diseases in China for several years; however, the underlying mechanism remains unclear. The aim of this study is to investigate the protective effect of PF against atRAL toxicity in human ARPE-19 cells and its molecular mechanism. The results of our study showed that the pre-treatment of PF dose-dependently attenuated atRAL-induced cell injury by the reduction of Nox1/ROS-associated oxidative stress, mitochondrial dysfunction and GRP78-PERK-eIF2α-ATF4-CHOP-regulated endoplasmic reticulum (ER) stress in ARPE-19 cells. Additionally, our data showed that PF mainly exerted its activity via triggering calcium-calmodulin dependent protein kinase II (CaMKII)-mediated activation of AMP-activated protein kinase (AMPK). AMPK inhibition significantly reversed the protective effect of PF against atRAL toxicity in ARPE-19 cells. Overall, our findings provided the novel mechanism of PF protecting human RPE cells, which may prevent the progression of retinal degenerative diseases.


Sujet(s)
AMP-Activated Protein Kinases/métabolisme , Calcium-Calmodulin-Dependent Protein Kinase Type 2/métabolisme , Calcium/métabolisme , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Glucosides/pharmacologie , Mitochondries/effets des médicaments et des substances chimiques , Monoterpènes/pharmacologie , Stress oxydatif/effets des médicaments et des substances chimiques , Épithélium pigmentaire de la rétine/cytologie , Apoptose/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Chaperonne BiP du réticulum endoplasmique , Activation enzymatique/effets des médicaments et des substances chimiques , Humains , Mitochondries/métabolisme , Mitochondries/anatomopathologie , Espèces réactives de l'oxygène/analyse , Espèces réactives de l'oxygène/métabolisme , Épithélium pigmentaire de la rétine/effets des médicaments et des substances chimiques , Rétinal/analogues et dérivés , Rétinal/antagonistes et inhibiteurs , Rétinal/pharmacologie
14.
J Cosmet Dermatol ; 17(6): 1136-1143, 2018 Dec.
Article de Anglais | MEDLINE | ID: mdl-30027612

RÉSUMÉ

BACKGROUND: Glycolic acid (GA) chemical peels are a popular treatment for photoaged skin rejuvenation, but retinaldehyde (RAL)-based cosmetic creams have also demonstrated efficacy in improving photoaging, and are potentially better tolerated than chemical peels. AIMS: To compare the efficacy and safety of an antiaging cream containing 0.1% RAL associated with Glycylglycine Oleamide (GGO, Relastide® ) and Pre-tocopheryl® , to GA peels sessions in the treatment of photoaging. PATIENTS AND METHODS: Fifty-five women with photoaging were randomized in 2 treatment groups: (1) Daily application of the antiaging cream for 8 weeks or (2) Three sequential GA peels (20%, 50%, and 70%), 2-3 weeks apart. Skin surface texture, length of wrinkles, complexion radiance, and evenness of pigmentation and texture were assessed by profilometry using skin replicas, computer image analysis, and self-assessment. RESULTS: Efficacy of both treatments was similar in reducing crow's feet wrinkles depth (STm -7.61%, P = .0007 vs -4.34%, P = .0348; P = .3049 intergroup) and volume, crow's feet and periorbital wrinkle length, and number of fine lines and wrinkles at end of treatments. The efficacy of the cream in refining skin texture was superior to the peels (contrast: -5.61%, P = .0025 vs +3.54, P = .08; P intergroup = .0252). The 8-week treatment with the antiaging cream was well tolerated; adverse events were fewer and of milder intensity than with the peels, (12-fold lower incidence of physical signs). CONCLUSION: A dermocosmetic cream containing 0.1% RAL, GGO (Relastide® ) and Pre-tocopheryl® is as effective as 3 sequential GA peels, better tolerated, and is an alternative in the management of photoaged skin.


Sujet(s)
Exfoliation chimique , Glycolates/pharmacologie , Kératolytiques/pharmacologie , Rétinal/pharmacologie , Vieillissement de la peau/effets des médicaments et des substances chimiques , Vitamine E/analogues et dérivés , Adulte , Femelle , Humains , Adulte d'âge moyen , Crème pour la peau , Résultat thérapeutique , Vitamine E/pharmacologie
15.
Biochim Biophys Acta Mol Basis Dis ; 1864(9 Pt B): 2938-2948, 2018 09.
Article de Anglais | MEDLINE | ID: mdl-29890221

RÉSUMÉ

The largest class of rhodopsin mutations causing autosomal dominant retinitis pigmentosa (adRP) is mutations that lead to misfolding and aggregation of the receptor. The misfolding mutants have been characterized biochemically, and categorized as either partial or complete misfolding mutants. This classification is incomplete and does not provide sufficient information to fully understand the disease pathogenesis and evaluate therapeutic strategies. A Förster resonance energy transfer (FRET) method was utilized to directly assess the aggregation properties of misfolding rhodopsin mutants within the cell. Partial (P23H and P267L) and complete (G188R, H211P, and P267R) misfolding mutants were characterized to reveal variability in aggregation properties. The complete misfolding mutants all behaved similarly, forming aggregates when expressed alone, minimally interacting with the wild-type receptor when coexpressed, and were unresponsive to treatment with the pharmacological chaperone 9-cis retinal. In contrast, variability was observed between the partial misfolding mutants. In the opsin form, the P23H mutant behaved similarly as the complete misfolding mutants. In contrast, the opsin form of the P267L mutant existed as both aggregates and oligomers when expressed alone and formed mostly oligomers with the wild-type receptor when coexpressed. The partial misfolding mutants both reacted similarly to the pharmacological chaperone 9-cis retinal, displaying improved folding and oligomerization when expressed alone but aggregating with wild-type receptor when coexpressed. The observed differences in aggregation properties and effect of 9-cis retinal predict different outcomes in disease pathophysiology and suggest that retinoid-based chaperones will be ineffective or even detrimental.


Sujet(s)
Chaperons moléculaires/pharmacologie , Agrégation pathologique de protéines/anatomopathologie , Pliage des protéines/effets des médicaments et des substances chimiques , Rétinite pigmentaire/génétique , Rhodopsine/métabolisme , Diterpènes , Transfert d'énergie par résonance de fluorescence , Cellules HEK293 , Humains , Chaperons moléculaires/usage thérapeutique , Mutation , Agrégation pathologique de protéines/traitement médicamenteux , Agrégation pathologique de protéines/génétique , Protéines recombinantes/composition chimique , Protéines recombinantes/génétique , Protéines recombinantes/métabolisme , Rétinal/pharmacologie , Rétinal/usage thérapeutique , Rétinite pigmentaire/traitement médicamenteux , Rétinite pigmentaire/anatomopathologie , Rhodopsine/composition chimique , Rhodopsine/génétique
16.
Nat Commun ; 9(1): 1976, 2018 05 17.
Article de Anglais | MEDLINE | ID: mdl-29773803

RÉSUMÉ

Rhodopsin homeostasis is tightly coupled to rod photoreceptor cell survival and vision. Mutations resulting in the misfolding of rhodopsin can lead to autosomal dominant retinitis pigmentosa (adRP), a progressive retinal degeneration that currently is untreatable. Using a cell-based high-throughput screen (HTS) to identify small molecules that can stabilize the P23H-opsin mutant, which causes most cases of adRP, we identified a novel pharmacological chaperone of rod photoreceptor opsin, YC-001. As a non-retinoid molecule, YC-001 demonstrates micromolar potency and efficacy greater than 9-cis-retinal with lower cytotoxicity. YC-001 binds to bovine rod opsin with an EC50 similar to 9-cis-retinal. The chaperone activity of YC-001 is evidenced by its ability to rescue the transport of multiple rod opsin mutants in mammalian cells. YC-001 is also an inverse agonist that non-competitively antagonizes rod opsin signaling. Significantly, a single dose of YC-001 protects Abca4 -/- Rdh8 -/- mice from bright light-induced retinal degeneration, suggesting its broad therapeutic potential.


Sujet(s)
Neuroprotecteurs/pharmacologie , Pliage des protéines/effets des médicaments et des substances chimiques , Dégénérescence de la rétine/traitement médicamenteux , Cellules photoréceptrices en bâtonnet de la rétine/effets des médicaments et des substances chimiques , Rhodopsine/métabolisme , Thiophènes/pharmacologie , Transporteurs ABC/génétique , Alcohol oxidoreductases/génétique , Animaux , Lignée cellulaire tumorale , Modèles animaux de maladie humaine , Diterpènes , Femelle , Cellules HEK293 , Tests de criblage à haut débit , Humains , Lumière/effets indésirables , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Mutation , Cellules NIH 3T3 , Neuroprotecteurs/usage thérapeutique , Transport des protéines/effets des médicaments et des substances chimiques , Transport des protéines/génétique , Dégénérescence de la rétine/étiologie , Dégénérescence de la rétine/anatomopathologie , Cellules photoréceptrices en bâtonnet de la rétine/métabolisme , Cellules photoréceptrices en bâtonnet de la rétine/anatomopathologie , Cellules photoréceptrices en bâtonnet de la rétine/effets des radiations , Rétinal/pharmacologie , Rétinal/usage thérapeutique , Rhodopsine/agonistes , Rhodopsine/antagonistes et inhibiteurs , Rhodopsine/génétique , Thiophènes/usage thérapeutique , Résultat thérapeutique
17.
Mol Pharmacol ; 93(5): 438-452, 2018 05.
Article de Anglais | MEDLINE | ID: mdl-29453250

RÉSUMÉ

The retinoid (visual) cycle consists of a series of biochemical reactions needed to regenerate the visual chromophore 11-cis-retinal and sustain vision. Genetic or environmental factors affecting chromophore production can lead to blindness. Using animal models that mimic human retinal diseases, we previously demonstrated that mechanism-based pharmacological interventions can maintain vision in otherwise incurable genetic diseases of the retina. Here, we report that after 9-cis-retinal administration to lecithin:retinol acyltransferase-deficient (Lrat-/- ) mice, the drug was rapidly absorbed and then cleared within 1 to 2 hours. However, when conjugated to form chitosan-9-cis-retinal, this prodrug was slowly absorbed from the gastrointestinal tract, resulting in sustainable plasma levels of 9-cis-retinol and recovery of visual function without causing elevated levels, as occurs with unconjugated drug treatment. Administration of chitosan-9-cis-retinal conjugate intravitreally in retinal pigment epithelium-specific 65 retinoid isomerase (RPE65)-deficient dogs improved photoreceptor function as assessed by electroretinography. Functional rescue was dose dependent and maintained for several weeks. Dosing via the gastrointestinal tract in canines was found ineffective, most likely due to peculiarities of vitamin A blood transport in canines. Use of the chitosan conjugate in combination with 11-cis-6-ring-retinal, a locked ring analog of 11-cis-retinal that selectively blocks rod opsin consumption of chromophore while largely sparing cone opsins, was found to prolong cone vision in Lrat-/- mice. Development of such combination low-dose regimens to selectively prolong useful cone vision could not only expand retinal disease treatments to include Leber congenital amaurosis but also the age-related decline in human dark adaptation from progressive retinoid cycle deficiency.


Sujet(s)
Cécité/thérapie , Chitosane/administration et posologie , Chitosane/composition chimique , Cellules photoréceptrices de vertébré/effets des médicaments et des substances chimiques , Rétinal/administration et posologie , Rétinal/composition chimique , Acyltransferases/génétique , Administration par voie orale , Animaux , Chitosane/pharmacologie , Opsines des cônes/métabolisme , Modèles animaux de maladie humaine , Diterpènes , Chiens , Relation dose-effet des médicaments , Électrorétinographie , Femelle , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Opsines/métabolisme , Épithélium pigmentaire de la rétine/cytologie , Épithélium pigmentaire de la rétine/effets des médicaments et des substances chimiques , Épithélium pigmentaire de la rétine/métabolisme , Rétinal/pharmacologie , Opsines des bâtonnets/métabolisme , Tomographie par cohérence optique
18.
J Drug Target ; 26(4): 333-344, 2018 04.
Article de Anglais | MEDLINE | ID: mdl-28895754

RÉSUMÉ

This study depicts coenzyme Q10 (CoQ10) and retinaldehyde (RAL) co-loaded nanostructured lipid carriers (NLCs); having activity on different targets of photoageing, which can overcome deficits of conventional topical dosage forms. The developed NLCs were characterised for particle size, polydispersity index and percent entrapment efficiency (%EE), followed by their incorporation into Carbopol® 934 P-NF gel. In vitro cellular uptake and cytotoxicity assay was performed to evaluate NLCs and in vivo study on ultraviolet- (UV) induced wrinkle model to determine efficacy of NLCs. The developed stable, homogenous and spherical NLCs with size range of 200-230 nm and more than 80 %EE, showed prolonged, biphasic in vitro release pattern for CoQ10 and RAL. Ex vivo study portrayed negligible permeation through skin but appreciable penetration and distribution in skin layers. This has shown good uptake of both drugs with least cytotoxicity in cell culture studies. In vivo irritation study on Sprague Dawley (SD) rats and pharmacodynamic study on female Swiss albino mice proved it less irritant and efficacious. The developed NLCs thus hold promise in the efficient management of wrinkle and their reduction as indicated by the data obtained.


Sujet(s)
Lipides/composition chimique , Rétinal/administration et posologie , Vieillissement de la peau/effets des médicaments et des substances chimiques , Ubiquinones/analogues et dérivés , Animaux , Lignée cellulaire , Vecteurs de médicaments/composition chimique , Systèmes de délivrance de médicaments , Libération de médicament , Femelle , Humains , Souris , Nanostructures , Taille de particule , Rats , Rat Sprague-Dawley , Rétinal/pharmacocinétique , Rétinal/pharmacologie , Absorption cutanée , Ubiquinones/administration et posologie , Ubiquinones/pharmacocinétique , Ubiquinones/pharmacologie
19.
Vis Neurosci ; 34: E004, 2017 01.
Article de Anglais | MEDLINE | ID: mdl-28359344

RÉSUMÉ

Vertebrate rod and cone photoreceptors require continuous supply of chromophore for regenerating their visual pigments after photoactivation. Cones, which mediate our daytime vision, demand a particularly rapid supply of 11-cis retinal chromophore in order to maintain their function in bright light. An important contribution to this process is thought to be the chromophore precursor 11-cis retinol, which is supplied to cones from Müller cells in the retina and subsequently oxidized to 11-cis retinal as part of the retina visual cycle. However, the molecular identity of the cis retinol oxidase in cones remains unclear. Here, as a first step in characterizing this enzymatic reaction, we sought to determine the subcellular localization of this activity in salamander red cones. We found that the onset of dark adaptation of isolated salamander red cones was substantially faster when exposing directly their outer vs. their inner segment to 9-cis retinol, an analogue of 11-cis retinol. In contrast, this difference was not observed when treating the outer vs. inner segment with 9-cis retinal, a chromophore analogue which can directly support pigment regeneration. These results suggest, surprisingly, that the cis-retinol oxidation occurs in the outer segments of cone photoreceptors. Confirming this notion, pigment regeneration with exogenously added 9-cis retinol was directly observed in the truncated outer segments of cones, but not in rods. We conclude that the enzymatic machinery required for the oxidation of recycled cis retinol as part of the retina visual cycle is present in the outer segments of cones.


Sujet(s)
Cellules photoréceptrices en cône de la rétine/physiologie , Segment externe de cellule photoréceptrice rétinienne/physiologie , Vision/physiologie , Rétinol/métabolisme , Ambystoma , Animaux , Adaptation à l'obscurité , Diterpènes , Microspectrophotométrie , Oxydoréduction , Stimulation lumineuse , Pigments rétiniens/métabolisme , Rétinal/pharmacologie
20.
Neurosci Res ; 123: 1-7, 2017 Oct.
Article de Anglais | MEDLINE | ID: mdl-28433627

RÉSUMÉ

Retinal tissues generated from human pluripotent stem cells can be an excellent tool for investigating pathogenesis of retinal diseases and developing new pharmacologic therapies. Moreover, patient derived retinal tissues could allow for retinal transplantation therapy for degenerative retinal diseases. However, obtaining retinal tissues with matured photoreceptor outer segments, which are essential for photoreceptor functions, is currently challenging. Here we investigated the effects of docosahexaenoic acid (DHA) for maturation of photoreceptor outer segments at the late stage and visual chromophore analog, 9-cis-retinal for the early stage of differentiation to three-dimensional (3D)-retinal tissues from human embryonic stem cells (hESCs), respectively. In the presence of DHA, differentiated 3D-retinal tissues demonstrated improved maturation of photoreceptor outer segments and increased number of photoreceptor cells compared with tissues without DHA. Increased mRNA expression of mature photoreceptor markers was additionally documented in retinal tissues cultured with DHA. Conversely supplementation with 9-cis-retinal failed to improve differentiation of retinal tissues perhaps due to chronic aldehyde toxicity. The current study demonstrated that the addition of DHA to culture medium can help promote differentiation of photoreceptor outer segments in vitro and utilization of this methodology may lead to future therapies for patients with blinding diseases.


Sujet(s)
Différenciation cellulaire/effets des médicaments et des substances chimiques , Acide docosahexaénoïque/pharmacologie , Cellules photoréceptrices/effets des médicaments et des substances chimiques , Rétine/cytologie , Analyse de variance , Animaux , Protéines de transport/génétique , Protéines de transport/métabolisme , Diterpènes , Cellules souches embryonnaires/effets des médicaments et des substances chimiques , Cellules souches embryonnaires/physiologie , Protéines de l'oeil/génétique , Protéines de l'oeil/métabolisme , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , ARN messager/métabolisme , Recovérine/génétique , Recovérine/métabolisme , Rétine/effets des médicaments et des substances chimiques , Rétinal/pharmacologie , Rhodopsine/génétique , Rhodopsine/métabolisme , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...